WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
How to treat CML patients who are resistant to inhibitors of BCR-ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib-treated CML in which intradermally administered WT1 peptide vaccine elicited WT1-specific immune responses and the resultant reduction in the persistent residual disease in co-administration of Imatinib. BCR-ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR-ABL mRNA levels was associated with the increase in frequency of WT1-specific cytotoxic T lymphocytes, notably effector-memory type of that, in the patient's peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure-oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.
Oji
Yusuke
Y
Department of Cancer Stem Cell Biology Respiratory Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Oka
Yoshihiro
Y
Nishida
Sumiyuki
S
Tsuboi
Akihiro
A
Kawakami
Manabu
M
Shirakata
Toshiaki
T
Takahashi
Kazuko
K
Murao
Ayako
A
Nakajima
Hiroko
H
Narita
Miwako
M
Takahashi
Masuhiro
M
Morita
Satoshi
S
Sakamoto
Junichi
J
Tanaka
Toshio
T
Kawase
Ichiro
I
Hosen
Naoki
N
Sugiyama
Haruo
H
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D018365:Neoplasm, Residual; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D012333:RNA, Messenger; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use; D025721:WT1 Proteins / Q000737:chemistry / Q000276:immunology*
D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D022223:Vaccines, Subunit; D025721:WT1 Proteins; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl